Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Strategic News Service (SNS) is a global technology and economic forecasting organization that provides high-level strategic intelligence to executives, investors, and policymakers. Founded by Mark Anderson, the company is renowned for its SNS Global Report and the annual Future in Review (FiRe) conference, which are recognized for their high predictive accuracy regarding technological shifts. While not a therapeutic developer, SNS maintains a significant presence in the life sciences through its SNS Health initiative, which focuses on the intersection of biology, technology, and the global economy. The firm provides deep-dive analysis into emerging trends such as genomics, proteomics, and personalized medicine, serving as a strategic advisor to leaders in the biotechnology and pharmaceutical industries. Its work often explores how advanced computing and artificial intelligence are transforming drug discovery and healthcare delivery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Strategic News Service.